Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022
Curis, Inc. (NASDAQ: CRIS) plans to report its third quarter 2022 financial results on November 9, 2022, after U.S. market closure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) plans to report its third quarter 2022 financial results on November 9, 2022, after U.S. market closure. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results. Curis is known for developing innovative cancer therapeutics, including collaborations on various immuno-oncology projects. Notably, the TakeAim Leukemia trial of emavusertib is on a partial clinical hold, impacting new patient enrollment.
Positive
- None.
Negative
- The TakeAim Leukemia trial has a partial clinical hold, preventing new patient enrollment in combination phases.
- Current participants may continue only at 300mg BID or lower doses.
Details
News Market Reaction – CRIS
The recorded move for CRIS in the trading session of this news was -4.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Nov. 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET.
To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax and expansion phase (Phase 2a), and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2022-financial-results-and-hold-conference-call-on-november-9-2022-301666109.html
SOURCE Curis, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.